Oragenics, Inc.

Oragenics, Inc. is a U. S. -based biotechnology company specializing in the development of innovative medical technologies, particularly in pharmaceuticals and vaccines, aimed at addressing significant unmet clinical needs.

Founded in Tampa, US, Oragenics, Inc. is focused on developing advanced medical therapies. The company has undergone strategic pivots to prioritize the development of ONP-002, a drug targeting brain-related conditions. Notable funding includes a total of USD 16.

50 mn raised across several rounds, primarily aimed at advancing its pipeline products, including the pivotal ONP-002. Oragenics, Inc. develops innovative medical technologies to address unmet clinical needs, particularly in pharmaceuticals and vaccines. Its primary product, ONP-002, is in clinical development for brain-related conditions, targeting healthcare institutions, research facilities, and pharmaceutical partners within the United States, with potential for international market expansion in the future.

The company generates revenue through strategic partnerships and collaborations focusing on the development and commercialization of its pharmaceutical products. Oragenics engages in B2B agreements with pharmaceutical companies and research institutions, facilitating joint development agreements and licensing arrangements tied to its lead product, ONP-002. Specific transaction details adhere to industry standards, reflecting the value of its proprietary technologies. Oragenics plans to expand its product offerings by launching ONP-002 and potentially other products targeting unmet medical needs.

The company is exploring market expansion into international regions as development progresses. Recent funding will support these initiatives, enhancing their capacity for product development and market entry strategies.